Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.58 |
| ▸ | TYMP | P19971 | 4/20 | 0.48 |
| ▸ | PYGM | P11217 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908658 | 1.00 | TK2 (0.58) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL767851 | 1.00 | TK2 (0.58) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL9908664 | 0.92 | TK2 (0.52) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL767848 | 0.92 | TK2 (0.52) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL767769 | 0.92 | TK2 (0.52) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL767906 | 0.92 | TK2 (0.52) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL9908659 | 0.92 | TK2 (0.52) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL9908668 | 0.92 | TK2 (0.52) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL15216156 | 0.92 | TK2 (0.60) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL16943136 | 0.92 | TK2 (0.60) | TK2TYMPPYGMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011123621-A2 | 2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011005861-A9 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011005861-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | TK2 219/4885TYMP 183/4885PYGM 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.